Zacks Investment Research lowered shares of ChemoCentryx, Inc. (NASDAQ:CCXI) from a buy rating to a hold rating in a research report report published on Monday morning.

According to Zacks, “ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. “

A number of other equities research analysts have also recently commented on CCXI. Cowen and Company reiterated a hold rating on shares of ChemoCentryx in a research note on Tuesday, August 8th. BidaskClub cut ChemoCentryx from a strong-buy rating to a buy rating in a research note on Thursday, August 10th. Finally, ValuEngine cut ChemoCentryx from a hold rating to a sell rating in a research note on Saturday, October 21st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company’s stock. ChemoCentryx presently has a consensus rating of Hold and an average target price of $8.25.

ChemoCentryx (CCXI) traded up $0.08 during midday trading on Monday, hitting $7.49. The stock had a trading volume of 59,000 shares, compared to its average volume of 141,167. ChemoCentryx has a 12 month low of $6.13 and a 12 month high of $10.80.

ChemoCentryx (NASDAQ:CCXI) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.26) by $0.13. research analysts predict that ChemoCentryx will post -0.67 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “ChemoCentryx, Inc. (CCXI) Downgraded by Zacks Investment Research to Hold” was published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/11/13/chemocentryx-inc-ccxi-downgraded-by-zacks-investment-research-to-hold.html.

A number of institutional investors have recently made changes to their positions in the stock. American Century Companies Inc. raised its stake in ChemoCentryx by 1.7% in the 2nd quarter. American Century Companies Inc. now owns 41,442 shares of the biopharmaceutical company’s stock valued at $388,000 after acquiring an additional 698 shares during the period. Wells Fargo & Company MN raised its stake in ChemoCentryx by 3.2% in the 2nd quarter. Wells Fargo & Company MN now owns 23,595 shares of the biopharmaceutical company’s stock valued at $221,000 after acquiring an additional 729 shares during the period. Teachers Advisors LLC raised its stake in ChemoCentryx by 3.9% in the 2nd quarter. Teachers Advisors LLC now owns 41,878 shares of the biopharmaceutical company’s stock valued at $392,000 after acquiring an additional 1,590 shares during the period. The Manufacturers Life Insurance Company raised its stake in ChemoCentryx by 14.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,514 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 2,852 shares during the period. Finally, Voya Investment Management LLC raised its stake in ChemoCentryx by 22.8% in the 2nd quarter. Voya Investment Management LLC now owns 15,984 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 2,965 shares during the period. Institutional investors and hedge funds own 49.15% of the company’s stock.

ChemoCentryx Company Profile

ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.

Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.